BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hypothalamus
,
Autoimmunity
,
Lovastatin
,
rs7903146
,
SIRT1
,
cell-cell adhesion
,
Ischemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
daratumumab
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Myeloma OPM-2 cells with conditional IKZF1 or IKZF3 knockout or treated with lenalidomide
Explore Curated Studies Results
Literature
Most Relevant Literature
Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multipl…
Acute leukoencephalopathy associated with daratumumab treatment in POEMS syndrome: a case report.
Outcomes of COVID-19 in multiple myeloma patients treated with daratumumab.
Pharmacodynamic-Mediated Drug Disposition (PDMDD) Model of Daratumumab Monotherapy in Patients with …
A rare case of daratumumab-associated encephalopathy in multiple myeloma.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Daratumumab in Primary Antiphospholipid Syndrome
The DART Study- Daratumumab Treatment in ITP
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
A Study of Daratumumab
Desensitization in Kidney Allograft Using Daratumumab
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ